Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Learn more about:
Related Clinical Trial
A Phase II Trial Evaluating the Efficacy of Cabozantinib With Patients With Refractory GCTs Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors A Study of a New Way to Treat Children With a Brain Tumor Called NGGCT Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Symptom Management for YA Cancer Survivors A Study of miRNA 371 in Patients With Germ Cell Tumors Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Aflac ST0901 CHOANOME – Sirolimus in Solid Tumors Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) A Pilot RCT of the PRISM Intervention for AYAs With Cancer Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Molecular-Guided Therapy for Childhood Cancer EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Busulfan in Treating Children and Adolescents With Refractory CNS Cancer CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven’t Responded to Therapy ABT-751 in Treating Young Patients With Refractory Solid Tumors Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Collecting and Storing Tissue From Young Patients With Cancer Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Everolimus in Refractory Testicular Germ Cell Cancer Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS) A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors First Line TIP in Poor Prognosis TGCTs. Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Disulfiram and Cisplatin in Refractory TGCTs. Role of Axumin PET Scan in Germ Cell Tumor Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors Study Evaluating the Impact of Short Message Service on Compliance With Surveillance of Patients With Germ-cell Tumors Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01 Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors Germ Cell Tumor and Testicular Tumor DNA Registry A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

Brief Title

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Official Title

Dasatinib With Ifosfamide, Carboplatin, Etoposide: A Pediatric Phase I/II Trial

Brief Summary

      RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and
      etoposide, work in different ways to stop the growth of tumor cells, either by killing the
      cells or by stopping them from dividing. Giving dasatinib together with ifosfamide,
      carboplatin, and etoposide may kill more tumor cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when
      given together with ifosfamide, carboplatin, and etoposide and to see how well they work in
      treating young patients with metastatic or recurrent malignant solid tumors.
    

Detailed Description

      OBJECTIVES:

      Primary

        -  To determine the maximum tolerated dose (MTD) of dasatinib when given immediately
           following ifosfamide, carboplatin, and etoposide phosphate (D-ICE) as a re-induction
           regimen in young patients with metastatic or recurrent malignant solid tumors. (Phase I)

        -  To describe and define the toxicities of D-ICE in these patients. (Phase I)

        -  To determine the safety and feasibility of prolonged administration of single-agent
           dasatinib following completion of 2-6 courses of D-ICE in these patients. (Phase I)

        -  To estimate the overall survival, progression-free survival, and time to progression in
           patients treated with D-ICE at the MTD followed by single-agent dasatinib. (Phase II)

        -  To estimate the response rate to two courses of D-ICE when given at the MTD in these
           patients. (Phase II)

      Secondary

        -  To determine the phosphotyrosine state of SRC family kinases and related signaling
           pathways, including FAK, STAT3, VEGFR, AKT, EGFR, KIT, EPHA2, and PDGFR, in
           paraffin-embedded tumor samples as measured by immunohistochemistry prior to and during
           treatment with dasatinib.

        -  To assess gene expression profiling in fresh frozen tissue samples as measured by
           microarray analysis (Affymetrix GeneChips) at baseline to identify molecular signatures
           that may predict response to dasatinib.

        -  To correlate biomarkers and molecular signatures with dasatinib dosage, toxicity, and
           antitumor activity.

        -  To evaluate the effect of dasatinib on phosphorylation of SRC family kinases in
           peripheral blood mononuclear cell samples as a surrogate marker of response prior to
           treatment with dasatinib, at days 14-21 or when WBC ≥ 500/μL, during each treatment
           course, at the time of local control, and at the time of progression.

      OUTLINE: This is a multicenter, phase I, dose-escalation study of dasatinib followed by a
      phase II study. Patients enrolled in phase II are stratified according to disease.

      Patients receive D-ICE comprising oral dasatinib twice daily on days 5-21, ifosfamide IV over
      1 hour and etoposide phosphate IV over 1 hour on days 1-5, and carboplatin IV over 1 hour on
      days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease
      progression or unacceptable toxicity. Patients then undergo radiotherapy and/or surgery
      (consolidation therapy) after 2, 4, or 6 courses of D-ICE. After completion of consolidation
      therapy, patients receive oral dasatinib twice daily for up to 6 months in the absence of
      disease progression or unacceptable toxicity.

      Tumor tissue and peripheral blood mononuclear cell (PBMC) samples are collected periodically
      for correlative laboratory studies. PBMCs are analyzed by western blotting for total and
      phospho-SRC, phospho-FAK, and other relevant biomarkers. Tumor tissue samples are analyzed by
      IHC for total and phospho-SRC, phospho-FAK, phospho-STAT3, phospho-KIT, and phospho-PDGFR,
      EPHA2, and VEGF. Tumor tissue samples are also analyzed by microarray gene expression
      profiling to define a potential molecular signature or gene expression pattern that may
      predict response to dasatinib.

      After completion of study treatment, patients are followed periodically.
    

Study Phase

Phase 1/Phase 2

Study Type

Interventional


Primary Outcome

Maximum tolerated dose of dasatinib (Phase I)

Secondary Outcome

 Response rate prior to consolidation therapy as measured by RECIST criteria (Phase II)

Condition

Brain and Central Nervous System Tumors

Intervention

carboplatin

Study Arms / Comparison Groups

 Dasatinib with Ifosfamide, Carboplatin, Etoposide
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

143

Start Date

September 3, 2008

Completion Date

December 31, 2021

Primary Completion Date

August 24, 2010

Eligibility Criteria

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed malignant solid tumor that did not respond to or relapsed
             after standard first-line chemotherapy or other antineoplastic therapy (if the
             standard therapy for the tumor is generally recognized to be beneficial)

               -  Must have been initially diagnosed with malignancy prior to 25 years of age

               -  Radiographic, nuclear image, or biopsy confirmation of disease within the past 4
                  weeks

          -  Meets one of the following criteria:

               -  Phase I: Relapsed/refractory malignant solid tumor (excluding CNS tumors)

                    -  Patients with recurrent or metastatic disease that was completely resected
                       just prior to study entry are eligible

               -  Phase II: Patients are stratified according to one of the following diagnoses:

                    -  Stratum A: Relapsed sarcoma (rhabdomyosarcoma, osteosarcoma, or Ewing
                       sarcoma)

                    -  Stratum B: Other relapsed solid tumors, including any of the following:

                         -  Other soft tissue sarcomas

                         -  Kidney tumors

                         -  Lymphoma

                         -  CNS tumors*

                         -  Other solid tumors (neuroblastoma, gonadal and germ cell tumors, liver
                            tumors, or miscellaneous tumors)

                    -  Stratum C: Newly diagnosed, poor-risk metastatic sarcoma consisting of
                       unresectable pulmonary metastases (≥ 6 nodules) and/or disease involving
                       multiple bones or other organs NOTE: *Patients with recurrent primary CNS
                       tumors are eligible for the phase II portion of this study provided there
                       are no significant intratumoral bleeding toxicities seen in either COG
                       pediatric phase I studies of dasatinib or the phase I portion of this study

          -  Radiographically measurable disease (Phase II)

               -  Measurable disease is not required for patients who are enrolled in the phase I
                  portion of this study

          -  No bone marrow involvement (Phase I)

               -  Patients with bone marrow involvement are eligible for the phase II portion of
                  this study provided they are not known to be refractory to red cell or platelet
                  transfusions

        PATIENT CHARACTERISTICS:

          -  Lansky performance status (PS) 50-100% (patients 1-16 years of age) or Karnofsky PS
             50-100% (patients > 16 years of age)

          -  Life expectancy ≥ 8 weeks

          -  ANC > 1,000/μL

          -  Platelet count > 75,000/μL

          -  Creatinine clearance or GFR ≥ 70 mL/min OR creatinine < 1.5 times upper limit of
             normal (ULN)

          -  Bilirubin < 1.5 times ULN for age

          -  SGOT or SGPT < 2.5 times ULN for age (< 5 times ULN if liver involvement by tumor)

          -  Ejection fraction normal by MUGA OR shortening fraction > 28%

          -  No evidence of cardiac arrhythmias requiring therapy

          -  Corrected QTc interval < 450 msecs

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to comply with the safety monitoring requirements of this study

          -  No uncontrolled infection

          -  No swallowing dysfunction that would preclude oral medication intake

               -  Gastric or jejunal tube allowed provided it is functioning

          -  No history of significant bleeding disorder unrelated to cancer, including the
             following:

               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)

               -  Acquired bleeding disorder diagnosed within the past year (e.g., acquired
                  anti-factor VIII antibodies)

               -  Ongoing or recent (within the past 3 months) significant gastrointestinal
                  bleeding

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from all prior therapy

          -  At least 7 days since prior and no concurrent drugs known to cause Torsades de
             Pointes, including the following:

               -  Procainamide or disopyramide

               -  Amiodarone, sotalol, ibutilide, or dofetilide

               -  Erythromycin or clarithromycin

               -  Chlorpromazine, haloperidol, mesoridazine, or thioridazine

               -  Bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine,
                  levomethadyl, pentamidine, sparfloxacin, or lidoflazine

          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosourea-containing therapy)

          -  At least 3 months since prior ifosfamide, carboplatin, and/or etoposide phosphate in
             the exact combination and dosage as administered in this study

          -  More than 7 days since prior filgrastim (G-CSF), sargramostim (GM-CSF), or
             interleukin-11

          -  More than 14 days since prior pegfilgrastim

          -  More than 30 days since prior epoetin alfa

          -  No prior cranial-spinal irradiation at doses > 2,400 cGy

          -  No prior radiotherapy, including total-body irradiation, to > 50% of the bone marrow
             space

          -  No other concurrent investigational drugs or anticancer agents

          -  No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital,
             felbamate, primdone, oxcarbazepine, or carbamazepine)

          -  No concurrent anti-thrombotic or anti-platelet agents (e.g., warfarin, heparin, low
             molecular weight heparin, aspirin, ibuprofen, or other NSAIDs)

          -  No concurrent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, or voriconazole)

          -  No concurrent highly active antiretroviral therapy for HIV-positive patients

          -  No concurrent St. John's wort

          -  No IV bisphosphonates during the first 8 weeks of dasatinib therapy
      

Gender

All

Ages

1 Year - 25 Years

Accepts Healthy Volunteers

No

Contacts

Judith K. Sato, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT00788125

Organization ID

07053

Secondary IDs

P30CA033572

Responsible Party

Sponsor

Study Sponsor

City of Hope Medical Center

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Judith K. Sato, MD, Principal Investigator, City of Hope Comprehensive Cancer Center


Verification Date

March 2021